Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
BridgeBio Pharma
Biotech
BridgeBio's cancer spinout backs SPAC as path to Nasdaq
The biotech—which spun out of BridgeBio Pharma in May 2024—has $100 million cash to hand, while Helix is bringing $196 million to the table.
James Waldron
Feb 28, 2025 9:25am
BridgeBio cuts gene therapy budget as clinical data disappoint
Sep 11, 2024 7:50am
BridgeBio’s offshoot GondolaBio launches with $300M
Aug 21, 2024 11:36am
Moderna, Terremoto, MEI Pharma and more—Chutes & Ladders
Jul 26, 2024 8:30am
BridgeBio posts BioMarin-beating data on dwarfism drug prospect
Jun 4, 2024 7:30am
BridgeBio taps VCs for $200M to fund cancer-focused spinout
May 2, 2024 7:00am
